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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the comparative benefits and harms of different lifestyle interventions in the treatment of non-alcohol related fatty liver disease.
B A C K G R O U N D
Description of the condition
Fatty liver disease is steatosis (accumulation of fat, usually triglyc-
erides) in the parenchymal cells of the liver (NCBI 2018). Non-
alcohol related fatty liver disease (also called non-alcoholic fatty
liver disease (NAFLD)) is liver steatosis in the absence of signifi-
cant alcohol consumption; use of medications such as methotrex-
ate, tamoxifen, or steroids; or other disorders that result in fat
accumulation, such as hepatitis C virus infection, Wilson’s dis-
ease, starvation, and lecithin cholesterol acyltransferase (LCAT)
deficiency (Angulo 2002; Chalasani 2012). Fatty liver disease in-
cludes a spectrum of disorders ranging from simple steatosis or
non-alcoholic fatty liver (NAFL) (fat accumulation without evi-
dence of injury to the parenchymal cells of the liver), non-alco-
holic steatohepatitis (NASH) (fat accumulation with injury to the
liver’s parenchymal cells but without cirrhosis), to NASH cirrhosis
(advanced liver fibrosis with current or previous NAFL or NASH)
(Chalasani 2012; Rinella 2015). However, it has to be noted that
the existing non-invasive tests to distinguish NAFLD from alco-
hol-related liver disease (ALD) are only about 75% to 90% accu-
rate and some patients with ALDmay be misclassified as NAFLD
(Cerovic 2013; Wang 2016).
The prevalence of NAFLD varies between 19% and 33% in differ-
ent populations, depending upon ethnicity, region of origin (also
among people of similar ethnicity), being overweight or obese,
and having other disorders such as diabetes mellitus or hyper-
tension (Bedogni 2005; Park 2006; Dassanayake 2009; Koehler
2012; Lazo 2013; Fleischman 2014; Li 2014; Shen 2014; Nishioji
2015). The major risk factors associated with increased preva-
lence of NAFLD are obesity, being male, increasing age, ethnic-
ity (e.g. Mexican-Americans have higher prevalence of fatty liver
than other ethnic groups), genetic susceptibility (e.g. genetic vari-
ation in patatin-like phospholipase domain containing 3 gene),
hypertension, hypercholesterolaemia, diabetes mellitus, lower so-
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cioeconomic status, lower level educational attainment, poor sleep
pattern, and lower physical activity (Bedogni 2005; Park 2006;
Dassanayake 2009; Sookoian 2011; Koehler 2012; Lazo 2013;
Fleischman 2014; Shen 2014; Bernsmeier 2015; Lonardo 2015).
The mean age of people with NAFLD varies between 40 years
and 60 years (Bedogni 2005; Dassanayake 2009; Shen 2014). In
studies with long-term follow-up, the mean age of people with
NAFLD has ranged between 45 years and 50 years (Adams 2005;
Bedogni 2007; Soderberg 2010; Onnerhag 2014). After a mean
follow-up period of eight to 28 years, the presence of NAFLD in-
creased overall long-termmortality compared to the general popu-
lation without NAFLD (Adams 2005; Bedogni 2007; Ong 2008;
Soderberg 2010; Onnerhag 2014).
People with NAFLD are at risk of dying before reaching the mean
life expectancy at birth (Adams 2005; Bedogni 2007; Ong 2008;
Soderberg 2010; Onnerhag 2014). It is widely believed that peo-
ple with simple steatosis rarely progress to advanced liver disease,
but people with NASH may develop cirrhosis (Chalasani 2012).
It has been reported that in people with NAFLD, liver fibrosis was
the only histological feature associated with increased mortality
and requirement for liver transplantation (Angulo 2015; Ekstedt
2015). In a study that followed people with simple steatosis and
NASH for a mean of 28 years, similar rates of mortality were ob-
served between participants with simple steatosis and those with
NASH, but highermortality rates were observed in people with se-
vere fibrosis regardless of whether they had bland steatosis (steato-
sis without inflammation) or NASH (Soderberg 2010). It is note-
worthy that NAFLD is associated with metabolic syndrome, that
is, presence of three of the following factors: hypertension, raised
triglycerides, lowered high-density lipoprotein cholesterol, raised
fasting glucose, and central obesity (Alberti 2009; Ballestri 2016).
Therefore, increased mortality in people with NAFLD may be
related to metabolic syndrome, rather than NAFLD alone. Fur-
thermore, ALD has worse prognosis that NAFLD (Dam-Larsen
2005); the difficulty in distinguishing NAFLD from ALD may
also contribute to the higher mortality observed in NAFLD.
Non-alcohol related fatty liver disease is currently one of the most
common causes of liver transplantation: since 2008, NAFLD has
been either the second or third most common reason for liver
transplantation each year, and the number of people who under-
went liver transplantation for NAFLD has been similar to that of
alcohol-related liver disease since 2008 (Cholankeril 2017). The
risk of hepatocellular carcinoma (HCC), the most common type
of primary liver cancer in adults, is higher in people with NASH
cirrhosis compared to people with NAFLD without cirrhosis and
the general population: approximately 2% to 13% of people with
NASH cirrhosis develop HCC in three to seven years (White
2012). However, HCC can occur in people with NAFLD without
them having cirrhosis (Piscaglia 2016).
Fat accumulates within the liver cells when there is an imbalance
between the mechanisms that reduce fat in cells (such as oxidation
of fatty acids or secretion of lipoproteins) and mechanisms that
increase fat in cells (such as increased uptake of fat and increased
production of fat). The accumulation of fat leading to NAFLD is
believed to be mediated by insulin resistance, because insulin resis-
tance increases the breakdown of peripheral adipose tissue which
results in increased influx of free fatty acids (FFA), promotes the
synthesis of new triglycerides within the liver, and decreases the
oxidation of FFAs (Abdelmalek 2007; Buzzetti 2016). The accu-
mulation of fat in the liver causes injury due to pro-inflamma-
tory cytokines (Riley 2007). However, the mechanism by which
only a proportion of people develop advanced liver fibrosis or
primary liver cancer (hepatocellular cancer or HCC) is unclear
(Abdelmalek 2007). A ’multiple parallel hits’ model - involving
nutrition, gut bacteria, and accumulation of fat leading to liver
inflammation - has been proposed to explain the development and
progression of NAFLD (Tilg 2010).
Ultrasound is a widely usedmethod for screening the general pop-
ulation for NAFLD; however, it is operator-dependent (Hernaez
2011), and may miss 15 people with fatty liver disease out of every
100 people screened (Hernaez 2011). It may also yield false-pos-
itive results in seven out of 100 people without fatty liver disease
(Hernaez 2011). While liver biopsy can be considered the defini-
tive investigation to confirm the diagnosis, it is invasive and not
suitable for screening the general population.
Description of the intervention
Various interventions have been tried in the treatment of peo-
ple with NAFLD. This review will examine lifestyle modifica-
tions such as dietary changes and/or increased physical activity
(Abenavoli 2015; Shojaee-Moradie 2016; Zhang 2016;Houghton
2017) (the focus of the present systematic review). Other interven-
tions not included in this review include nutritional supplemen-
tation (probiotics, prebiotics, synbiotics, vitamin supplementa-
tion, polyunsaturated fatty acid supplementation) (Nabavi 2014;
Sharifi 2014; Li 2015; Nogueira 2016; Mofidi 2017); pharma-
cological interventions (Lombardi 2017); and weight reduction
surgery (bariatric surgery) in obese people with NAFLD (Adorini
2012; Anstee 2012; Chalasani 2012; Paschos 2012; Abenavoli
2013a). While liver biopsy can be considered the definitive inves-
tigation to confirm the diagnosis, it is invasive and not suitable for
screening the general population.
How the intervention might work
Lifestyle modifications, such as dietary changes and increased
physical activity, are aimed at decreasing weight and serum lipid
profile (Abenavoli 2015; Shojaee-Moradie 2016; Zhang 2016;
Houghton 2017). This may lead to resolution or decrease the pro-
gression of fatty liver disease (Chalasani 2012). Dietary modifica-
tionsmay also decrease insulin resistance and increase antioxidants,
leading to improvement inNAFLD, and improve the vitamins and
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other micronutrients available naturally from the food (Conlon
2013). Poor sleep pattern is associated with an increased risk of
NAFLD due to its correlation with insulin resistance (Bernsmeier
2015). Lifestyle interventions aimed at improving sleep pattern
may therefore improve NAFLD by decreasing insulin resistance.
Nutritional supplementation (not included in this review) may
work in different ways: vitamin E decreases oxidative damage to
liver cells (Chalasani 2012); the effect of vitamin D supplemen-
tation may be mediated through its ability to decrease inflamma-
tory markers and lipid peroxidation (Sharifi 2014), that of probi-
otics may be mediated through its ability to decrease inflamma-
tory markers and alter lipid profile (Al-Muzafar 2017), and that
of polyunsaturated fatty acids may be mediated through ability to
alter lipid profile (Chalasani 2012). This may lead to resolution
or decrease progression of fatty liver disease. There is currently no
effective pharmacological intervention in people with NAFLD or
NASH; however, there is significant uncertainty about the effect
of pharmacological interventions on NAFLD (Lombardi 2017).
The reasons for investigating these pharmacological interventions
(not included in this review) have been based on their potential
to decrease weight, insulin resistance, and/or oxidative damage to
liver cells, alter lipid profile, or their anti-inflammatory and anti-
fibrotic properties (Adorini 2012; Anstee 2012; Chalasani 2012;
Thoma 2012; Abenavoli 2013a). Surgeries resulting in weight loss
(not included in this review) may improve fatty liver by reducing
weight (Chalasani 2012).
Why it is important to do this review
Currently, there is no effective pharmacological treatment for
NAFLD with or without NASH (Lombardi 2017). Research on
treatments to decrease NAFLD and NASH have been identified
as top research priorities by patients, carers, and healthcare profes-
sionals involved in the treatment of liver diseases inUK (Gurusamy
2018a). Lifestyle modifications have the potential to result in reso-
lution or to decrease the progression of fatty liver disease. Network
meta-analysis enables direct and indirect evidence to be combined,
and different interventions to be ranked in terms of different out-
comes (Salanti 2011; Salanti 2012). There has been no previous
Cochrane Review on this topic. Therefore, it is important to assess
the benefits and harms of lifestyle modifications in the treatment
of people with NAFLD. If it is not possible to perform this review
using network meta-analysis methods, for example, if the transi-
tivity assumption (please see below) is unlikely to be met, we will
instead use standard Cochrane methods to perform meta-analy-
sis of head-to-head comparisons whenever possible. We will also
present results from direct comparisons whenever possible, even if
we perform the network meta-analysis.
O B J E C T I V E S
To assess the comparative benefits and harms of different lifestyle
interventions in the treatment of non-alcohol related fatty liver
disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider only randomised clinical trials for this network
meta-analysis, irrespective of language, publication status, or date
of publication. We will exclude studies of other designs because of
the risk of bias in such studies. Inclusion of indirect observational
evidence could weaken our network meta-analysis, but this could
also be viewed as a strength for assessing rare adverse events. It is
well established that exclusionof non-randomised studies increases
the focus on potential benefits and reduces the focus on the risks
of serious adverse events and those of any adverse events. However,
because of the exponentially increased amount of work required
to include non-randomised studies, we will exclude them from
the current review. We will register and perform a new systematic
review and meta-analysis of non-randomised studies for adverse
events if there is uncertainty in the balance of benefits and harms
of effective treatment(s).
Types of participants
We will include randomised clinical trials with participants who
have non-alcohol related fatty liver disease (NAFLD), irrespective
of the method of diagnosis, age and diabetic status of participants,
or presence of non-alcoholic steatohepatitis (NASH). We will ex-
clude randomised clinical trials in which participants have previ-
ously undergone liver transplantation.
Types of interventions
We will include any of the following interventions for comparison
with one another, either alone or in combination.
• Supervised physical activity (for example, exercise classes)
• General physical activity advice
• Rationed diet (for example, daily or weekly rations of
different foods, calorie restricted diet)
• Special diets (for example, Mediterranean diet, Atkin’s diet,
high-fibre diet, or diet with high fruit and vegetable content)
• General dietary advice (for example, information on the fat
or carbohydrate content of different foods)
• Lifestyle modifications that promote sleep (for example,
nicotine and caffeine restriction)
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• No active intervention (including sham or placebo
interventions).
We will include trials in which the above interventions were com-
bined with other interventions aimed at decreasing NAFLD (but
will consider these as potential effect modifiers), provided that
these cointerventions are administered equally in both arms. We
will include nutritional supplements (in form of tablets, powder,
or solution) in a different review (Gurusamy 2018b).
We will evaluate the plausibility of the transitivity assumption (the
assumption that participants included in the different trials with
different treatments for NAFLD can be considered to be a part of
a multi-arm randomised clinical trial and could potentially have
been randomised to any of the interventions) (Salanti 2012), by
looking at the inclusion and exclusion criteria in the studies. In
other words, any participant that meets the inclusion criteria is,
in principle, equally likely to be randomised to any of the above
eligible interventions. This necessitates that information on po-
tential effect-modifiers such as diabetic status and cointerventions
status are similar across trials. If there is any concern about the
transitivity assumption, we will perform separate meta-analysis for
each of these different types of participants.
Types of outcome measures
Primary outcomes
• All-cause mortality at maximal follow-up (time to death).
• Health-related quality of life, as defined in the included
trials, using a validated scale such as the EQ-5D or 36-Item
Short Form Health Survey (SF-36) (EuroQol 2018; Optum
2018) at maximal follow-up.
• Serious adverse events (during or within six months after
cessation of intervention). We define a serious adverse event as
any event that would increase mortality; is life-threatening;
requires hospitalisation; results in persistent or significant
disability; is a congenital anomaly/birth defect; or any important
medical event that might jeopardise the person or require
intervention to prevent it (ICH-GCP 1997). However, we will
use the definitions used by study authors for serious adverse
events.
◦ Proportion of trial participants with one or more
serious adverse event
◦ Number of serious adverse events per participant
Secondary outcomes
• Any adverse events (during or within six months after
cessation of intervention). We define an adverse event as any
untoward medical occurrence not necessarily having a causal
relationship with the intervention but resulting in a dose
reduction or discontinuation of intervention (any time after
commencement of intervention) (ICH-GCP 1997). However,
we will use the definition used by study authors for adverse
events.
◦ Proportion of trial participants with any adverse events
◦ Number of any adverse events per participant
• Time to liver transplantation (maximal follow-up)
• Time to decompensation (maximal follow-up)
• Time to cirrhosis (maximal follow-up)
Exploratory outcomes
• Time to resolution of fatty liver disease (maximal follow-up)
• Fibrosis score at maximal follow-up
• NAFLD activity score
We have chosen outcomes based on:
• their importance to patients in a survey related to research
priorities for people with liver diseases (Gurusamy 2018a);
• feedback from the patient and public representative of this
project; and
• an online survey about the outcomes promoted through the
Cochrane Consumer Network.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library, MEDLINEOvid, Embase
Ovid, and Science Citation Index Expanded (Web of Science),
from inception to date of search, for randomised clinical trials
comparing two or more of the above interventions, without ap-
plying any language restrictions (Royle 2003). We will search for
all possible comparisons formed by the interventions of interest.
To identify further ongoing or completed trials, we will also search
clinicaltrials.gov, and the World Health Organization Interna-
tional Clinical Trials Registry Platform (apps.who.int/trialsearch/)
which searches various trial registers, including ISRCTNandClin-
icalTrials.gov. We will also search the European Medical Agency
( EMA) ( www.ema.europa.eu/ema/) and US Food and Drug
Administration ( FDA) ( www.fda.gov) registries for randomised
clinical trials. The provisional search strategies are provided in
Appendix 1. To improve efficiency in study selection, this review
will share the same search strategy as another review on nutritional
supplementation in people with NAFLD (Gurusamy 2018b).
Searching other resources
To identify additional trials for inclusion, we will search the ref-
erences of the identified trials and the existing Cochrane Reviews
on non-alcohol related fatty liver disease.
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Data collection and analysis
Selection of studies
Two review authors (KG and a research assistant) will indepen-
dently identify trials for inclusion by screening the titles and ab-
stracts and will seek full-text articles for any references identified
by at least one of the review authors for potential inclusion. We
will select trials for inclusion based on the full-text articles.We will
provide the list of references that we excluded and the reasons for
their exclusion in the ’Characteristics of excluded studies’ table.
We will also list any ongoing trials identified primarily through
the search of the clinical trial registers for further follow-up. We
will resolve any discrepancies through discussion.
Data extraction and management
Two review authors (KG and a research assistant) will indepen-
dently extract the following data using a piloted Microsoft Excel-
based data extraction form (after translation of non-English arti-
cles).
• Outcome data (for each outcome and for each intervention
group whenever applicable):
◦ number of participants randomised;
◦ number of participants included for the analysis;
◦ number of participants with events for binary
outcomes, mean and standard deviation for continuous
outcomes, number of events and the mean follow-up period for
count outcomes, and number of participants with events and the
mean follow-up period for time-to-event outcomes;
◦ natural logarithm of hazard ratio and its standard
error, if this was reported, rather than the number of participants
with events and the mean follow-up period for time-to-event
outcomes;
◦ definition of outcomes or scale used, if appropriate.
• Data on potential effect modifiers:
◦ participant characteristics such as age, sex, diabetic
status, method of diagnosis, presence of NASH;
◦ details of the intervention and control (including
intensity (for exercise interventions) (CDC 2018), or type of diet
(for example, low-fat diet, high-protein diet, Mediterranean
diet), frequency, and duration);
◦ length of follow-up;
◦ information related to ’Risk of bias’ assessment (please
see below).
• Other data:
◦ year and language of publication;
◦ country in which the participants were recruited;
◦ year(s) in which the trial was conducted;
◦ inclusion and exclusion criteria.
We will collect outcomes at maximum follow-up but also at short
term (up to three months) and medium term (from three months
to five years) if these data are available.
We will contact the trial authors in the case of unclear or missing
information. If there is any doubt as to whether trials shared the
same participants, completely or partially (by identifying common
authors and centres), we will attempt to contact the trial authors
to clarify whether the trial report was duplicated. Any differences
in opinion will be resolved through discussion.
Assessment of risk of bias in included studies
We will follow the guidance in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011) and the Cochrane
Hepato-Biliary Group Module (Gluud 2018) to assess the risk of
bias in included trials. Specifically, we will assess sources of bias as
defined below (Schulz 1995;Moher 1998; Kjaergard 2001;Wood
2008; Savovi 2012a; Savovi 2012b; Lundh 2017; Savovi
2018).
Allocation sequence generation
• Low risk of bias: the study authors performed sequence
generation using computer random number generation or a
random number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice are adequate if performed by an
independent person not otherwise involved in the study. In
general, we will classify the risk of bias as low if the method used
for allocation concealment suggested that it was extremely likely
that the sequence was generated randomly (for example, use of
interactive voice response system).
• Unclear risk of bias: the study authors did not specify the
method of sequence generation.
• High risk of bias: the sequence generation method was not
random.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. A central and
independent randomisation unit controlled allocation. The
investigators are unaware of the allocation sequence (e.g. if the
allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so that the intervention
allocations may have been foreseen before, or during, enrolment.
• High risk of bias: it is likely that the investigators who
assigned the participants knew the allocation sequence. We will
exclude such quasi-randomised studies.
5Lifestyle modifications for non-alcohol related fatty liver disease: a network meta-analysis (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Blinding of participants and personnel
• Low risk of bias: blinding of participants and key study
personnel was ensured, and it was unlikely that the blinding
could have been broken; or rarely no blinding or incomplete
blinding, but the review authors judged that the outcome was
not likely to be influenced by lack of blinding.
• Unclear risk of bias: no blinding or incomplete blinding,
and the outcome was likely to be influenced by lack of blinding;
or blinding of key study participants and personnel was
attempted, but it was likely that the blinding could have been
broken, and the outcome was likely to be influenced by lack of
blinding.
Blinded outcome assessment
• Low risk of bias: no blinding of outcome assessment, but
the review authors judged that the outcome measurement was
not likely to be influenced by lack of blinding; or blinding of
outcome assessment was ensured, and it was unlikely that the
blinding could have been broken.
• Unclear risk of bias: insufficient information to permit
judgement of ’low risk’ or ’high risk’; or the trial did not address
this outcome.
• High risk of bias: no blinding of outcome assessment, and
the outcome measurement was likely to be influenced by lack of
blinding; or blinding of outcome assessment, but it was likely
that the blinding could have been broken, and the outcome
measurement was likely to be influenced by lack of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The study used
sufficient methods, such as multiple imputation, to handle
missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported the following predefined
outcomes: at least one of the outcomes related to the main reason
for treatment of people with NAFLD, namely, all-cause
mortality or resolution of NAFLD, along with adverse events. If
the original trial protocol was available, the outcomes should
have been those called for in that protocol. If the trial protocol
was obtained from a trial registry (e.g. ClinicalTrials.gov), the
outcomes sought should have been those enumerated in the
original protocol if the trial protocol was registered before or at
the time that the trial was begun. If the trial protocol was
registered after the trial was begun, those outcomes will not be
considered to be reliable.
• Unclear risk of bias: not all predefined, or clinically relevant
and reasonably expected, outcomes were reported fully, or it was
unclear whether data on these outcomes were recorded or not.
• High risk of bias: one or more predefined or clinically
relevant and reasonably expected outcomes were not reported,
despite the fact that data on these outcomes should have been
available and even recorded.
For-profit bias
• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support that could
manipulate the trial design, conductance, or results of the trial
(industry-sponsored trials overestimate the efficacy by about
25%) (Lundh 2017).
• Uncertain risk of bias: the trial may or may not have been
free of for-profit bias, as no information on clinical trial support
or sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received other type of for-profit support.
Other bias
• Low risk of bias: the trial appeared to be free of other
components that could put it at risk of bias (e.g. inappropriate
control or dose or administration of control, baseline differences,
early stopping).
• Uncertain risk of bias: the trial may or may not have been
free of other components that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias (e.g. baseline differences, early
stopping).
We will consider a trial to be at low risk of bias if we assess the trial
to be at low risk of bias across all domains listed above. Otherwise,
we will consider trials to be at high risk of bias. At the outcome
level, we will classify an outcome to be at low risk of bias if the
allocation sequence generation, allocation concealment, blinding
of participants, healthcare professionals, and outcome assessors,
incomplete outcome data, and selective outcome reporting (at the
outcome level) are at low risk of bias for objective and subjective
outcomes (Savovi 2018).
Measures of treatment effect
Relative treatment effects
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For dichotomous variables (e.g. proportion of participants with
serious adverse events or any adverse events), we will calculate the
odds ratio (OR)with 95%credible interval (CrI) (or Bayesian con-
fidence interval) (Severini 1993). For continuous variables (e.g.
health-related quality of life reported on the same scale), we will
calculate the mean difference (MD) with 95% Crl. We will use
standardised mean difference (SMD) values with 95% Crl for
health-related quality of life if included trials use different scales.
For count outcomes (e.g. number of serious adverse events or num-
ber of any adverse events), we will calculate the rate ratio (RaR)
with 95% Crl. For time-to-event data (e.g. all-cause mortality at
maximal follow-up), we will calculate the hazard ratio (HR) with
95% Crl.
Relative ranking
We will estimate the ranking probabilities for all interventions of
being at each possible rank for each intervention. We will obtain
the surface under the cumulative ranking curve (SUCRA) (cumu-
lative probability), rankogram, and relative ranking table with CrI
for the ranking probabilities (Salanti 2011; Chaimani 2013).
Unit of analysis issues
The unit of analysis will be the participant undergoing treatment
for NAFLD, according to the intervention group to which the
participant was randomly assigned.
Cluster-randomised clinical trials
We will include cluster-randomised clinical trials provided that
the effect estimate adjusted for cluster correlation is available, or if
there is sufficient information to calculate the design effect from
the trial, as this will allow us to take clustering into account. We
will also assess additional domains of risk of bias for cluster-ran-
domised trials according to guidance in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011)
Cross-over randomised clinical trials
If we identify any cross-over randomised clinical trials, we will
include the outcomes after the period of first intervention, because
the included treatments can have residual effects.
Trials with multiple intervention groups
We will collect data for all trial intervention groups that meet
the inclusion criteria. The codes for analysis that we will use, will
account for the correlation between the effect sizes from studies
with more than two groups.
Dealing with missing data
We will perform an intention-to-treat analysis whenever possible
(Newell 1992); otherwise, we will use the data available to us.
This may result in the use of ’per-protocol’ analyses. Since these
may be biased, particularly if the data are not missing at random
(for example, the treatment was withdrawn due to adverse events,
or the duration of treatment was shortened because of lack of
response and such participants were excluded from analysis), we
will conduct best-worst case scenario analysis (which assumes a
good outcome in the intervention group and bad outcome in
the control group) and worst-best case scenario analysis (which
assumes a bad outcome in the intervention group and a good
outcome in the control group) as sensitivity analyses whenever
possible for dichotomous outcomes.
For continuous outcomes, we will impute the standard deviation
from P values according to guidance in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). If the data
are likely to be normally distributed, we will use the median for
meta-analysis when themean is not available. If it is not possible to
calculate the standard deviation from the P value or the confidence
intervals, we will impute the standard deviation using the largest
standard deviation in other trials for that outcome. This form of
imputation can decrease the weight of the study for calculation of
mean differences and may bias the effect estimate to no effect for
calculation of standardised mean differences (Higgins 2011).
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity by care-
fully examining the characteristics and design of included trials.
We will assess the presence of clinical heterogeneity by comparing
effect estimates for various subgroups (please see Subgroup analysis
and investigation of heterogeneity). Different study designs and
risk of bias can also contribute to methodological heterogeneity.
We will assess statistical heterogeneity by comparing the results of
the fixed-effectmodelmeta-analysis and the random-effectsmodel
meta-analysis, between-study standard deviation (tau2, and com-
paring this with values reported in study of the distribution of
between-study heterogeneity) (Turner 2012), and by calculating I
2 using Stata/SE 14.2. If we identify substantial clinical, method-
ological, or statistical heterogeneity, we will explore and address
the heterogeneity in subgroup analysis (see Subgroup analysis and
investigation of heterogeneity).
Assessment of transitivity across treatment
comparisons
We will assess the transitivity assumption by comparing the dis-
tribution of the following potential effect modifiers across the dif-
ferent pairwise comparisons.
• Clinical: people with and without diabetes, people with and
without NASH, different types of exercises/diets, and based on
the cointerventions.
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• Methodological: risk of bias, year of randomisation,
duration of follow-up).
Assessment of reporting biases
For the network meta-analysis, we will perform a comparison-
adjusted funnel plot. If there is no meaningful way in which to
rank these studies (i.e. there was no specific change in the risk of
bias in the studies, sample size, or the control group used over
time), we will judge the reporting bias by the completeness of the
search (Chaimani 2012).
Data synthesis
Methods for indirect and mixed comparisons
We will conduct network meta-analyses to compare multiple
interventions simultaneously for each of the primary and sec-
ondary outcomes. Network meta-analysis combines direct evi-
dence within trials and indirect evidence across trials (Mills 2012).
We will obtain a network plot to ensure that the trials are con-
nected by interventions using Stata/SE 14.2 (Chaimani 2013).
We will exclude any trials that are not connected to the network
from the networkmeta-analysis and report only the direct pairwise
meta-analysis for such comparisons. We will summarise the pop-
ulation and methodological characteristics of the trials included
in the network meta-analysis in a table based on pairwise com-
parisons. We will conduct a Bayesian network meta-analysis using
the Markov chain Monte Carlo method in OpenBUGS 3.2.3, ac-
cording to guidance from the National Institute for Health and
Care Excellence (NICE) Decision Support Unit (DSU) docu-
ments (Dias 2016). We will model the treatment contrast (i.e. log
odds ratio for binary outcomes, mean difference or standardised
mean difference for continuous outcomes, log rate ratio for count
outcomes, and log hazard ratio for time-to-event outcomes) for
any two interventions (’functional parameters’) as a function of
comparisons between each individual intervention and the refer-
ence group (’basic parameters’), using appropriate likelihood func-
tions and links (Lu 2006). We will use binomial likelihood and
logit link for binary outcomes, Poisson likelihood and log link for
count outcomes, binomial likelihood and complementary log-log
link (a semiparametric model which excludes censored individuals
from the denominator of ‘at risk’ individuals at the point when
they are censored), and normal likelihood and identity link for
continuous outcomes. We will use ’no active intervention’ as the
reference group. We will use a fixed-effect model and random-
effects model for the network meta-analysis. We will report both
models for comparison with the reference group in a forest plot.
For each pairwise comparison in a table, we will report the fixed-
effect model if the two models report similar results; otherwise,
we will report the more conservative model.
We will use a hierarchical Bayesian model using three different
initial values, employing codes provided by the NICE DSU (Dias
2016). We will use a normal distribution with large variance
(10,000) for treatment effect priors (vague or flat priors). For the
random-effects model, we will use a prior distributed uniformly
(limits: zero to five) for between-trial standard deviation but will
assume the same between-trial standard deviation across treatment
comparisons (Dias 2016). We will use a ’burn-in’ of 10,000 sim-
ulations, check for convergence (of effect estimates and between-
study heterogeneity) visually (i.e. whether the values in different
chains mix very well by visualisation), and run the models for an-
other 10,000 simulations to obtain effect estimates. If we do not
obtain convergence, we will increase the number of simulations
for the ’burn-in’. If we still do not obtain convergence, we will use
alternate initial values and priors employingmethods suggested by
van Valkenhoef 2012. We will estimate the probability that each
intervention ranks at one of the possible positions using the NICE
DSU codes (Dias 2016).
Assessment of inconsistency
We will assess inconsistency (statistical evidence of the violation
of transitivity assumption) by fitting both an inconsistency model
and a consistency model. We will use inconsistency models em-
ployed in the NICE DSU manual, as we will use a common be-
tween-study standard deviation (Dias 2014). In addition, we will
use design-by-treatment full interaction model and inconsistency
factor (IF) plots to assess inconsistency (Higgins 2012; Chaimani
2013).We will use Stata/SE 14.2 to create IF plots. In the presence
of inconsistency, we will assess whether the inconsistency was due
to clinical or methodological heterogeneity by performing sep-
arate analyses for each of the different subgroups mentioned in
Subgroup analysis and investigation of heterogeneity.
If there is evidence of inconsistency, we will identify areas in the
network where substantial inconsistency might be present in terms
of clinical and methodological diversities between trials and, when
appropriate, limit network meta-analysis to a more compatible
subset of trials.
Direct comparisons
We will perform the direct comparisons using the same codes and
the same technical details as described above.
Calculation of required information size and Trial Sequential
Analysis
For calculation of the required information size, see Appendix 2.
We will perform Trial Sequential Analysis for direct comparisons
to control the risk of random errors when at least two trials are in-
cluded for the comparison of other interventions versus no active
intervention (’control’), for the outcomes all-cause mortality at
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maximal follow-up and health-related quality of life, the two out-
comes that determine whether the intervention should be given
(Wetterslev 2008; Thorlund 2011; TSA 2011; Wetterslev 2017).
For all-cause mortality at maximal follow-up, we will use an al-
pha error according to the guidance of Jakobsen 2014 (i.e. 0.033),
power of 90% (beta error of 10%) (Castellini 2017), a relative risk
reduction of 20%, the median control group proportion observed
in the trials, and the heterogeneity observed in the meta-analysis
using Stata/SE14.2, employingmethods suggested byMiladinovic
and colleagues (Miladinovic 2013). For health-related quality of
life, a continuous outcome, we will use an alpha error according
to the guidance of Jakobsen 2014 (i.e. 0.033), power of 90% (beta
error of 10%) (Castellini 2017), a standardised mean difference of
0.2, the median health-related quality of life in the control group
in the trials, and the heterogeneity observed in the meta-analysis.
Subgroup analysis and investigation of heterogeneity
We plan to assess the differences in the effect estimates between
the following subgroups, and to investigate heterogeneity and in-
consistency using meta-regression with the help of the codes pro-
vided in the NICE DSU guidance if we include a sufficient num-
ber of trials (Dias 2012a). We plan to use the following trial-level
covariates for meta-regression.
• Trials at low risk of bias compared to trials at high risk of
bias.
• Participants with NASH compared to participants with
NAFLD but without NASH.
• Participants with diabetes mellitus compared to participants
without diabetes mellitus.
• Different types of exercises/diets.
• Cointerventions (for example, both groups receive omega-3
fatty acid supplementation).
• Period of follow-up (short term: up to three months;
medium term: more than three months to five years; long-term:
more than five years).
• Definition used by authors for serious adverse events and
any adverse events (ICH-GCP 1997 criteria versus other
definitions).
We will calculate a single common interaction term when appli-
cable (Dias 2012a). If the 95% CrI of the interaction term does
not overlap zero, we will consider this to represent statistically sig-
nificant heterogeneity.
Sensitivity analysis
If a trial reports only per-protocol analysis results, we plan to re-
analyse the results using the best-worst case scenario and worst-
best case scenario analyses as sensitivity analyseswhenever possible.
We will also perform a sensitivity analysis excluding the trials in
which mean or standard deviation, or both, were imputed and
use the median standard deviation in the trials to impute missing
standard deviations.
We will compare our assessments of imprecision with GRADE
methodology to that with Trial Sequential Analysis methodology
(Castellini 2018).
Presentation of results
We will follow the PRISMA-NMA statement while reporting
(Hutton 2015). We will present the effect estimates with 95%
CrI for each pairwise comparison calculated from the direct com-
parisons and network meta-analysis. We will also present the cu-
mulative probability of the treatment ranks (i.e. the probabil-
ity that the intervention is within the top two, the probabil-
ity that the intervention is within the top three, etc.) in graphs
(SUCRA) (Salanti 2011). We will plot the probability that each
intervention was best, second best, third best, etc. for each of
the different outcomes (rankograms), which are generally con-
sidered more informative (Salanti 2011; Dias 2012b). We will
also provide the CrI of the probabilities in the ranking proba-
bility tables. We will upload all the raw data and the codes used
for analysis in The European Organization for Nuclear Research
open source database (Zenodo) and provide a link within the re-
view.
Grading of evidence
We will present ’Summary of findings’ tables for all the pri-
mary and secondary outcomes (see Primary outcomes; Secondary
outcomes). We will follow the approach suggested by Puhan and
colleagues (Puhan 2014). First, we will calculate the direct and
indirect effect estimates and 95% CrI using the node-splitting
approach (Dias 2010), that is, calculating the direct estimate for
each comparison by including only trials in which there was direct
comparison of interventions, and the indirect estimate for each
comparison by excluding the trials in which there was direct com-
parison of interventions. Next we will rate the quality of direct and
indirect effect estimates using GRADE methodology which takes
into account the risk of bias, inconsistency, directness of evidence,
imprecision, and publication bias (Guyatt 2011). We will then
present the estimates of the network meta-analysis and rate the
quality of network meta-analysis effect estimates as the best qual-
ity of evidence between the direct and indirect estimates (Puhan
2014). In addition, we will present information on the absolute
measures (i.e. proportion of people with the outcome in each in-
tervention group based on the direct estimates, indirect estimates,
and network meta-analysis estimates). We will also present infor-
mation on the number of trials and participants, according to the
format of standard ’Summary of findings’ tables.
Recommendations for future research
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We will provide recommendations for future research in the pop-
ulation, intervention, control, outcomes, period of follow-up, and
study design based on the uncertainties that we identify from the
existing research.
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A P P E N D I C E S
Appendix 1. Search strategies
Database Time span Search strategy
Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library
Latest issue #1 MeSH descriptor: [Fatty Liver] explode
all trees
#2 (liver and (fatty or steatosis or steatoses)
)
#3 NAFLD
#4 #1 or #2 or #3
#5 (((Diet* or nutrition* or food*) and
Supplement*) or nutraceutical* or nu-
triceutical* or neutraceutical* or probiotic*
or prebiotic* or synbiotic* or lactobacill* or
bifidobacteria)
#6 MeSH descriptor: [Dietary Supple-
ments] explode all trees
#7 (vitamin* or micronutrient* or (trace
near/1 (element* or mineral*)) or antioxi-
dant*)
#8 MeSH descriptor: [Vitamins] explode
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(Continued)
all trees
#9 MeSH descriptor: [Micronutrients] ex-
plode all trees
#10 MeSH descriptor: [Antioxidants] ex-
plode all trees
#11 (((unsaturated or polyunsaturated)
and (fatty near/1 acid*)) or PUFA or
(linoleic near/1 acid*) or (docosahexaenoic
near/1 acid*) or (eicosapentaenoic near/1
acid))
#12MeSH descriptor: [Fatty Acids, Unsat-
urated] explode all trees
#13 #5 or #6 or #7 or #8 or #9 or #10 or
#11 or #12
#14 MeSH descriptor: [Exercise] this term
only
#15 MeSH descriptor: [Exercise Therapy]
this term only
#16 MeSH descriptor: [Physical Exertion]
this term only
#17 MeSH descriptor: [Motor Activity]
this term only
#18 MeSH descriptor: [Sports] this term
only
#19 (sport*)
#20MeSHdescriptor: [Physical Education
and Training] explode all trees
#21 (physical near/3 (activit* or education*
or exertion* or training))
#22 (exercise*)
#23 MeSH descriptor: [Diet Therapy] ex-
plode all trees
#24 ((diet or dieting) near/5 (health* or
weight*))
#25 (calorie near/3 (control or reduc* or
restriction))
#26 “food choice*”
#27 (“fat camp*” or “weight loss camp*”)
#28 “nutrition education”
#29 MeSH descriptor: [Nutrition Ther-
apy] this term only
#30 MeSH descriptor: [Behavior Therapy]
this term only
#31 MeSH descriptor: [Cognitive Ther-
apy] this term only
#32 MeSH descriptor: [Psychotherapy]
this term only
#33 (behavio?r* near/3 (therap* or tech-
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(Continued)
nique* or modif* or intervention*))
#34 (cognit* near/3 (therap* or technique*
or modif* or intervention*))
#35 CBT
#36 (psychotherap* or psycho-therap*)
#37 (psycho-social or psychosocial)
#38MeSHdescriptor: [Health Promotion]
explode all trees
#39 MeSH descriptor: [Health Education]
this term only
#40 (health* near/3 (promot* or educat* or
lifestyle))
#41MeSHdescriptor: [Life Style] this term
only
#42 (lifestyle* or life-style*)
#43 #14 or #15 or #16 or #17 or #18 or #
19 or #20 or #21 or #22 or #23 or #24 or
#25 or #26 or #27 or #28 or #29 or #30 or
#31 or #32 or #33 or #34 or #35 or #36 or
#37 or #38 or #39 or #40 or #41 or #42
#44 #13 or #43
#45 #4 and #44
MEDLINE Ovid January 1947 to date of search 1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp Fatty Liver/
13. (liver and (fatty or steatosis or steatoses)
).ti,ab.
14. NAFLD.ti,ab.
15. 12 or 13 or 14
16. (((Diet* or nutrition* or food*) and
Supplement*) or nutraceutical* or nu-
triceutical* or neutraceutical* or probiotic*
or prebiotic* or synbiotic* or lactobacill* or
bifidobacteria).ti,ab.
17. exp Dietary Supplements/
18. (vitamin* or micronutrient* or (trace
adj1 (element* or mineral*)) or antioxi-
dant*).ti,ab.
19. expVitamins/ or expMICRONUTRI-
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(Continued)
ENTS/ or exp ANTIOXIDANTS/
20. (((unsaturated or polyunsaturated) and
(fatty adj1 acid*)) or PUFA or (linoleic adj1
acid*) or (docosahexaenoic adj1 acid*) or
(eicosapentaenoic adj1 acid)).ti,ab.
21. exp Fatty Acids, Unsaturated/
22. 16 or 17 or 18 or 19 or 20 or 21
23. Exercise/ or Exercise Therapy/ or Phys-
ical Exertion/ orMotor Activity/ or Sports/
24. sport*.tw.
25. exp “Physical Education andTraining”/
26. (physical adj3 (activit* or education* or
exertion* or training)).tw.
27. exercise*.tw.
28. exp diet therapy/
29. ((diet or dieting) adj5 (health* or
weight*)).tw.
30. (calorie adj3 (control or reduc* or re-
striction)).tw.
31. food choice*.tw.
32. (fat camp* or weight loss camp*).tw.
33. nutrition education.tw.
34. Nutrition Therapy/ or behavior ther-
apy/ or Cognitive Therapy/ or psychother-
apy/
35. (behavio?r* adj3 (therap* or technique*
or modif* or intervention*)).tw.
36. (cognit* adj3 (therap* or technique* or
modif* or intervention*)).tw.
37. CBT.tw.
38. (psychotherap* or psycho-therap*).tw.
39. (psycho-social or psychosocial).tw.
40. exp Health Promotion/ or Health Ed-
ucation/
41. (health* adj3 (promot* or educat* or
lifestyle)).tw.
42. lifestyle/
43. (lifestyle* or life-style*).tw.
44. 23 or 24 or 25 or 26 or 27 or 28 or 29
or 30 or 31 or 32 or 33 or 34 or 35 or 36
or 37 or 38 or 39 or 40 or 41 or 42 or 43
45. 22 or 44
46. 11 and 15 and 45
Embase Ovid January 1974 to date of search 1. exp crossover-procedure/ or exp double-
blind procedure/ or exp randomized con-
trolled trial/ or single-blind procedure/
2. (((((random* or factorial* or crossover*
or cross over* or cross-over* or placebo* or
double*) adj blind*) or single*) adj blind*)
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(Continued)
or assign* or allocat* or volunteer*).af.
3. 1 or 2
4. exp fatty liver/
5. (liver and (fatty or steatosis or steatoses)
).ti,ab.
6. NAFLD.ti,ab.
7. 4 or 5 or 6
8. (((Diet* or nutrition* or food*) and Sup-
plement*) or nutraceutical* or nutriceuti-
cal* or neutraceutical* or probiotic* or pre-
biotic* or synbiotic* or lactobacill* or bifi-
dobacteria).ti,ab.
9. exp dietary supplement/ or probiotic
agent/ or prebiotic agent/ or synbiotic
agent/
10. (vitamin* or micronutrient* or (trace
adj1 (element* or mineral*)) or antioxi-
dant*).ti,ab.
11. exp vitamin/ or exp trace element/ or
exp antioxidant/
12. (((unsaturated or polyunsaturated) and
(fatty adj1 acid*)) or PUFA or (linoleic adj1
acid*) or (docosahexaenoic adj1 acid*) or
(eicosapentaenoic adj1 acid)).ti,ab.
13. exp polyunsaturated fatty acid/
14. 8 or 9 or 10 or 11 or 12 or 13
15. exercise/ or kinesiotherapy/ or motor
activity/ or sport/
16. sport*.tw.
17. (physical adj3 (activit* or education* or
exertion* or training)).tw.
18. exercise*.tw.
19. exp diet therapy/
20. ((diet or dieting) adj5 (health* or
weight*)).tw.
21. (calorie adj3 (control or reduc* or re-
striction)).tw.
22. food choice*.tw.
23. (fat camp* or weight loss camp*).tw.
24. nutrition education.tw.
25. behavior therapy/ or Cognitive Ther-
apy/ or psychotherapy/
26. (behavio?r* adj3 (therap* or technique*
or modif* or intervention*)).tw.
27. (cognit* adj3 (therap* or technique* or
modif* or intervention*)).tw.
28. CBT.tw.
29. (psychotherap* or psycho-therap*).tw.
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(Continued)
30. (psycho-social or psychosocial).tw.
31. exp Health Promotion/ or Health Ed-
ucation/
32. (health* adj3 (promot* or educat* or
lifestyle)).tw.
33. lifestyle/ or lifestyle modification/
34. (lifestyle* or life-style*).tw.
35. 15 or 16 or 17 or 18 or 19 or 20 or 21
or 22 or 23 or 24 or 25 or 26 or 27 or 28
or 29 or 30 or 31 or 32 or 33 or 34
36. 14 or 35
37. 3 and 7 and 36
Science Citation Index Expanded (Web of
Science)
January 1945 to date of search #1 TS = ((liver and (fatty or steatosis or
steatoses)) or NAFLD)
#2 TS=(((Diet* or nutrition* or food*)
and Supplement*) or nutraceutical* or nu-
triceutical* or neutraceutical* or probi-
otic* or prebiotic* or synbiotic* or lacto-
bacill* or bifidobacterial or vitamin* or mi-
cronutrient* or (trace near1 (element* or
mineral*)) or ((unsaturated or polyunsat-
urated) and (fatty near1 acid*)) or antiox-
idant* or PUFA or (linoleic near1 acid*)
or (docosahexaenoic near1 acid*) or (eicos-
apentaenoic near1 acid))
#3 TS=(sport* or (physical near/3 (activit*
or education* or exertion* or training)
) or exercise* or ((diet or dieting) near/
5 (health* or weight*)) or (calorie near/
3 (control or reduc* or restriction)) or
“food choice*” or “fat camp*” or “weight
loss camp*” or “nutrition education” or
(behavio?r* near/3 (therap* or technique*
or modif* or intervention*)) or (cognit*
near/3 (therap* or technique* or modif* or
intervention*)) or CBT or psychotherap*
or psycho-therap* or psycho-social or psy-
chosocial or (health* near/3 (promot* or
educat* or lifestyle)) or lifestyle* or life-
style* or (alcohol* near/2 (drink* or intox-
icat* or use* or abus* or misus* or risk* or
consum* or withdraw* or detox* or treat*
or therap* or excess* or reduc* or cessation
or intervention*)))
#4 #3 OR #2
#5 TS=(random* OR rct* OR crossover
OR masked OR blind* OR placebo* OR
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(Continued)
meta-analysis OR systematic review* OR
meta-analys*)
#6 #5 AND #4 AND #1
World Health Organization International
Clinical Trials Registry Platform (
apps.who.int/trialsearch/Default.aspx)
Date of search to be provided at review stage Condition: fatty liver
Phases: 2,3,4
ClinicalTrials.gov Date of search to be provided at review stage Fatty Liver, Nonalcoholic | Phase 2, 3, 4
European Medical Agency
(www.ema.europa.eu/ema/) and US Food
and Drug Administration (www.fda.gov)
Date of search to be provided at the review
stage
“Fatty liver”; random
Footnote: This is a common search strategy that will be used for this review and nutritional supplementation review (Gurusamy 2018b).
Appendix 2. Sample size calculation
The five-year mortality in people with non-alcohol related fatty liver disease is about 20% (Adams 2005). The required information
size based on a control group proportion of 20%, a relative risk reduction of 20% in the experimental group, type I error of 5%,
and type II error of 20% is 2894 participants. Network analyses are more prone to the risk of random errors than direct comparisons
(Del Re 2013). Accordingly, a greater sample size is required in indirect comparisons than direct comparisons (Thorlund 2012). The
power and precision in indirect comparisons depends upon various factors, such as the number of participants included under each
comparison and the heterogeneity between the trials (Thorlund 2012). If there is no heterogeneity across the trials, the sample size in
indirect comparisons would be equivalent to the sample size in direct comparisons. The effective indirect sample size can be calculated
using the number of participants included in each direct comparison (Thorlund 2012). For example, a sample size of 2500 participants
in the direct comparison A versus C (nAC ) and a sample size of 7500 participants in the direct comparison B versus C (nBC) results in
an effective indirect sample size of 1876 participants. However, in the presence of heterogeneity within the comparisons, the sample
size required is higher. In the above scenario, for an I² statistic for each of the comparisons A versus C (IAC
2) and B versus C (IBC
2) of
25%, the effective indirect sample size is 1407 participants. For an I² statistic for each of the comparisons A versus C and B versus C of
50%, the effective indirect sample size is 938 participants (Thorlund 2012). If there are only three groups and the sample size in the
trials is more than the required information size, we will calculate the effective indirect sample size using the following generic formula
(Thorlund 2012):
((nAC x (1 - IAC
2)) x (nBC x (1 - IBC
2))/((nAC x (1 - IAC
2)) + (nBC x (1 - IBC
2)).
Currently, there is no method to calculate the effective indirect sample size for a network analysis involving more than three intervention
groups.
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